Literature DB >> 11029379

Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study.

E S Yi1, H Kim, H Ahn, J Strother, T Morris, E Masliah, L A Hansen, K Park, P J Friedman.   

Abstract

We investigated the distribution of pulmonary arteriopathy in chronic pulmonary hypertension (PH) in a quantitative histopathologic study, using computer-assisted image analysis. We also examined the histologic manifestations and cellular phenotypes of various obstructive intimal lesions in PH with an immunohistochemical method. A total of 53 lungs removed at autopsy or explantation were obtained for the study from 51 documented cases of moderate to severe PH (15 cases of primary pulmonary hypertension [PPH], eight cases of Eisenmenger's syndrome [EISEN], 22 cases of chronic major-vessel thromboembolic disease [CTED], and three cases of PH associated with other known causes), and two unused donor lungs served as normal controls. Intimal thickening in PPH was most prominent in small pulmonary arteries and arterioles less than 200 micrometer in diameter. Plexiform lesions in PPH were associated with significantly smaller arteries than in EISEN. Arteries larger than 400 micrometer showed a significant intimal thickening only in CTED. Obstructive intimal lesions in PH comprised a morphologic spectrum with frequent intermediate forms between plexiform and thrombotic lesions. Most cells within various intimal lesions showed an immunoprofile of myofibroblasts that were positive for vimentin and alpha-smooth muscle actin, but negative for desmin and endothelial markers including Factor VIII, clonal designator (CD)31, and CD34. Endothelial markers were positive only in the single layer of cells lining slitlike lumens, when the latter were present. In conclusion, major types of PH had characteristic distribution patterns of obstructive intimal lesions, showing mainly a myofibroblastic phenotype and variable endothelial/vascular differentiation.

Entities:  

Mesh:

Year:  2000        PMID: 11029379     DOI: 10.1164/ajrccm.162.4.9912131

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  64 in total

Review 1.  New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Authors:  N Rudarakanchana; R C Trembath; N W Morrell
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

2.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

3.  Modern age pathology of pulmonary arterial hypertension.

Authors:  Elvira Stacher; Brian B Graham; James M Hunt; Aneta Gandjeva; Steve D Groshong; Vallerie V McLaughlin; Marsha Jessup; William E Grizzle; Michaela A Aldred; Carlyne D Cool; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

Review 4.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

5.  A variation of vasculopathies in a patient with mild pulmonary artery hypertension.

Authors:  Takao Kato; Takamasa Kitajima; Moriaki Inoko
Journal:  BMJ Case Rep       Date:  2013-09-11

Review 6.  Transdifferentiation of endothelial cells to smooth muscle cells play an important role in vascular remodelling.

Authors:  Núria Coll-Bonfill; Melina Mara Musri; Victor Ivo; Joan Albert Barberà; Olga Tura-Ceide
Journal:  Am J Stem Cells       Date:  2015-03-15

Review 7.  State of the art: utility of multi-energy CT in the evaluation of pulmonary vasculature.

Authors:  Prabhakar Rajiah; Yuki Tanabe; Sasan Partovi; Alastair Moore
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-02       Impact factor: 2.357

8.  Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression.

Authors:  Mun Chun Chan; Aaron C Hilyard; Connie Wu; Brandi N Davis; Nicholas S Hill; Ashish Lal; Judy Lieberman; Giorgio Lagna; Akiko Hata
Journal:  EMBO J       Date:  2009-12-17       Impact factor: 11.598

9.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Rod R Warburton; Nicholas S Hill; Barry L Fanburg; Iris Z Jaffe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

10.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.